American Journal of Ophthalmology
Volume 149, Issue 4 , Pages 550-561.e10 , April 2010

The Multicenter Uveitis Steroid Treatment Trial: Rationale, Design, and Baseline Characteristics

  • The Multicenter Uveitis Steroid Treatment Trial Research Group

      Affiliations

    • Ocular Inflammation Service, Department of Ophthalmology/Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania
    • Center for Preventive Ophthalmology and Biostatistics, Department of Ophthalmology/Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania
    • Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania
    • Fundus Photograph Reading Center, Department of Ophthalmology, University of Wisconsin, Madison, Wisconsin
    • Center for Clinical Trials, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland
    • Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland
    • Department of Biostatistics, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland
    • Departments of Ophthalmology and Medicine, The Mount Sinai School of Medicine, New York, New York
    • Corresponding Author InformationInquiries to John H. Kempen, Center for Preventive Ophthalmology and Biostatistics, Department of Ophthalmology, University of Pennsylvania, 3535 Market Street, Suite 700, Philadelphia, PA 19104; e-mail: john.kempen@uphs.upenn.edu
    • Corresponding Author InformationDouglas A. Jabs, MUST Chairman's Office, Department of Ophthalmology, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1183, New York, NY 10029-6574; e-mail: douglas.jabs@mssm.edu
    • Writing Committee: John H. Kempen, Michael M. Altaweel, Janet T. Holbrook, Douglas A. Jabs, and Elizabeth A. Sugar.

,Accepted 13 November 2009.

References 

  1. Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Ophthalmologica. 2004;218:223–236
  2. Nussenblatt RB. The natural history of uveitis. Int Ophthalmol. 1990;14:303–308
  3. ten Doesschate J. Causes of blindness in The Netherlands. Doc Ophthalmol. 1982;52:279–285
  4. National Advisory Eye Council. Vision Research (A National Plan, 1983–1987). In: Bethesda, MD: National Institutes of Health, Public Health Service, US Department of Health and Human Services; 1983;p. 13
  5. Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004;88:1159–1162
  6. Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol. 1987;103:234–235
  7. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data (Results of the First International Workshop). Am J Ophthalmol. 2005;140:509–516
  8. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332–336
  9. Henderly DE, Genstler AJ, Smith RE, Rao NA. Changing patterns of uveitis. Am J Ophthalmol. 1987;103:131–136
  10. McCannel CA, Holland GN, Helm CJ, Cornell PJ, Winston JV, Rimmer TG. Causes of uveitis in the general practice of ophthalmology (UCLA Community-Based Uveitis Study Group). Am J Ophthalmol. 1996;121:35–46
  11. Mercanti A, Parolini B, Bonora A, Lequaglie Q, Tomazzoli L. Epidemiology of endogenous uveitis in north-eastern Italy (Analysis of 655 new cases). Acta Ophthalmol Scand. 2001;79:64–68
  12. Merrill PT, Kim J, Cox TA, Betor CC, McCallum RM, Jaffe GJ. Uveitis in the southeastern United States. Curr Eye Res. 1997;16:865–874
  13. Palmares J, Coutinho MF, Castro-Correia J. Uveitis in northern Portugal. Curr Eye Res. 1990;9(Suppl):31–34
  14. Perkins ES, Folk J. Uveitis in London and Iowa. Ophthalmologica. 1984;189:36–40
  15. Pivetti-Pezzi P, Accorinti M, La Cava M, Colabelli Gisoldi RA, Abdulaziz MA. Endogenous uveitis: an analysis of 1,417 cases. Ophthalmologica. 1996;210:234–238
  16. Rodriguez A, Calonge M, Pedroza-Seres M, et al. Referral patterns of uveitis in a tertiary eye care center. Arch Ophthalmol. 1996;114:593–599
  17. Rothova A, Buitenhuis HJ, Meenken C, et al. Uveitis and systemic disease. Br J Ophthalmol. 1992;76:137–141
  18. Santin M, Badrinas F, Mascaro J, et al. Uveitis: an etiological study of 200 cases following a protocol [in Spanish]. Med Clin (Barc). 1991;96:641–644
  19. Smit RL, Baarsma GS, de Vries J. Classification of 750 consecutive uveitis patients in the Rotterdam Eye Hospital. Int Ophthalmol. 1993;17:71–76
  20. Tran VT, Auer C, Guex-Crosier Y, Pittet N, Herbort CP. Epidemiological characteristics of uveitis in Switzerland. Int Ophthalmol. 1994;18:293–298
  21. Foster CS, Vitale AT. Diagnosis and Treatment of Uveitis. Philadelphia: W. B. Saunders Company; 2002;
  22. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513
  23. Nussenblatt RB, Whitcup SM, Palestine AG. Uveitis (Fundamentals and Clinical Practice). St. Louis: Mosby; 1996;
  24. Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol. 2008;126:1191–1201
  25. Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113:1020–1027
  26. Jaffe GJ, Ben Nun J, Guo H, Dunn JP, Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000;107:2024–2033
  27. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996;
  28. Goldstein DA, Godfrey DG, Hall A, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol. 2007;125:1478–1485
  29. Beck RW, Maguire MG, Bressler NM, Glassman AR, Lindblad AS, Ferris FL. Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology. 2007;114:1804–1809
  30. Ferris FL, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982;94:91–96
  31. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–2816
  32. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131:541–560
  33. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin (one-year results of 2 randomized clinical trials—TAP report). Arch Ophthalmol. 1999;117:1329–1345
  34. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration (Results of a randomized clinical trial). Arch Ophthalmol. 1991;109:1220–1231
  35. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121–130
  36. Ryan P. sxd1_4: random allocation of treatments in blocks. Stata J. 2008;8:146
  37. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001;44:1496–1503
  38. Ferris FL, Bailey I. Standardizing the measurement of visual acuity for clinical research studies: guidelines from the Eye Care Technology Forum. Ophthalmology. 1996;103:181–182
  39. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53–72
  40. EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208
  41. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305:160–164
  42. Jenkinson C, Wright L, Coulter A. Criterion validity and reliability of the SF-36 in a population sample. Qual Life Res. 1994;3:7–12
  43. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119:1050–1058
  44. Hogan MJ, Kimura SJ, Thygeson P. Signs and symptoms of uveitis (I. Anterior uveitis). Am J Ophthalmol. 1959;47:155–170
  45. Mangione CM, Lee PP, Pitts J, Gutierrez P, Berry S, Hays RD. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ) (NEI-VFQ Field Test Investigators). Arch Ophthalmol. 1998;116:1496–1504
  46. Coons SJ, Rao S, Keininger DL, Hays RD. A comparative review of generic quality-of-life instruments. Pharmacoeconomics. 2000;17:13–35
  47. Musch DC, Lichter PR, Guire KE, Standardi CL. The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology. 1999;106:653–662
  48. Asman P, Heijl A. Glaucoma Hemifield Test (Automated visual field evaluation). Arch Ophthalmol. 1992;110:812–819
  49. Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans (The Baltimore Eye Survey). Arch Ophthalmol. 1991;109:1090–1095
  50. Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying cataracts from photographs: AREDS report no. 4. Am J Ophthalmol. 2001;131:167–175
  51. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183–1197
  52. Osteoporosis. review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis (Status Report). Osteoporos Int. 1998;8(Suppl 4):S3–S6
  53. Miller PD. Bisphosphonates for the prevention and treatment of corticosteroid-induced osteoporosis. Osteoporos Int. 2001;12(Suppl 3):S3–S10
  54. Kanis JA WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int. 1994;4:368–381
  55. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  56. Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Levy D. Differential impact of systolic and diastolic blood pressure level on JNC-VI staging (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure). Hypertension. 1999;34:381–385
  57. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413–2446
  58. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association; 2000;
  59. Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making. 2006;26:391–400
  60. Kacmaz RO, Kempen JH, Newcomb CW, et al. Ocular inflammation in Behçet's disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol. 2008;146:828–836
  61. Thorne JE, Jabs DA, Peters GB, Hair D, Dunn JP, Kempen JH. Birdshot retinochoroidopathy: ocular complications and visual impairment. Am J Ophthalmol. 2005;140:45–51
  62. Brown MM, Brown GC, Sharma S, Busbee B. Quality of life associated with visual loss: a time tradeoff utility analysis comparison with medical health states. Ophthalmology. 2003;110:1076–1081
  63. Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology. 2005;112:1192–1198
  64. BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. Transplant Proc. 1988;20:136–143
  65. Thorne JE, Wittenberg S, Jabs DA, et al. Multifocal choroiditis with panuveitis incidence of ocular complications and of loss of visual acuity. Ophthalmology. 2006;113:2310–2316
  66. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med. 1990;322:281–285

 Supplemental Material available at AJO.com.

PII: S0002-9394(09)00882-4

doi: 10.1016/j.ajo.2009.11.019

American Journal of Ophthalmology
Volume 149, Issue 4 , Pages 550-561.e10 , April 2010

Article Tools

* Image Usage & Resolution